早产儿声门上气道给予肺表面活性物质的可行性
首次2次内放置成功率98%,93%病例完成给药,给药后1小时中位FiO2由0.40降至0.25(P<.001),少数短暂低氧血症和心动过缓,无其他严重不良事件。
要点
- 早产儿专用声门上气道放置成功率高,首次尝试即成功占82%。
- 经声门上气道给药后1小时中位FiO2由0.40降至0.25(P<.001)。
- 出现3次血氧饱和度<60%和1次心率<60次/分,无其他操作相关严重不良事件。
核心结论
- 在出生体重800–1500 g的呼吸窘迫综合征早产儿中,使用早产儿专用声门上气道进行气道管理和肺表面活性物质给药是可行且耐受良好的。
主要发现
- 声门上气道放置成功率为98%,其中82%为首次尝试成功,27%的操作者为首次使用该装置。
- 成功放置气道的中位时间为21秒,整个操作中位持续5.4分钟。
- 93%的病例经声门上气道完成肺表面活性物质给药,给药后1小时中位吸入氧浓度由0.40降至0.25(P<.001)。
- 发生3次血氧饱和度<60%和1次心率<60次/分,未报告其他操作相关严重不良事件。
- 出生体重<1000 g与1000–1500 g婴儿在反应或不良事件方面未发现差异。
关键数值与推荐
- 纳入标准为出生体重750–1500 g且患呼吸窘迫综合征的早产儿,经父母知情同意后入组。
- 主要结局为2次尝试内成功放置声门上气道。
- 通过视频记录评估操作特征,并通过连续脉搏血氧监测评估生理稳定性。
临床怎么用
- 对于出生体重800–1500 g的呼吸窘迫综合征早产儿,可考虑使用早产儿专用声门上气道作为肺表面活性物质给药的可行途径。
- 操作中需持续监测血氧饱和度和心率,警惕短暂低氧血症和心动过缓的发生。
局限性
- 本研究为单臂可行性研究,样本量有限,无法与传统给药方式比较疗效和安全性。
- 研究结论需通过大型随机对照试验进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess feasibility and safety of airway management and surfactant administration using newly developed preterm-sized supraglottic airways (SAs) in infants with respiratory distress syndrome and birth weight 750 -1500 g. STUDY DESIGN: This investigator-initiated, single-arm interventional feasibility study was conducted in a level III neonatal intensive care unit at Phu San Hanoi Hospital (35 000 annual births). Infants with birth weights 750-1500 g were enrolled after parental consent. Surfactant was administered via preterm-sized SAs. The primary outcome was successful placement within 2 attempts. Video recordings were used to assess procedure characteristics and physiologic stability by continuous pulse oximetry. Data were summarized descriptively and compared for infants with weights of <1000 vs 1000-1500 g. RESULTS: Forty-five infants (median birth weight: 1300 g; range: 800-1500 g) were enrolled. SA placement was successful in 98% of cases, with 82% on the first attempt. For 27% of cases, this was the provider's first SA use. The median time to successful airway placement was 21 seconds, and the entire procedure lasted a median of 5.4 minutes. Surfactant was delivered by SA in 93% of cases and the median fraction of inspired oxygen decreased from 0.40 to 0.25 1 hour post-procedure (P < .001). Three desaturations (<60%) and one bradycardia (<60 beats per minute) occurred; no other procedure-related serious adverse events were reported. No differences in response or adverse events were found in infants with birth weight <1000g. CONCLUSIONS: Use of preterm sized SAs for surfactant delivery in infants weighing 800-1500 g was feasible and well tolerated. Large randomized controlled trials are needed to compare its efficacy and safety with conventional administration of surfactant. TRIAL REGISTRATION: ClinicalTrials.gov NCT06606444.
引用
- Larsson M, Vu H, Nguyen LT, et al. Feasibility of Surfactant Delivery via Preterm Supraglottic Airways in Infants with Birth Weights of 800-1500 g. J Pediatr. 2026. PMID: 42551730. doi:10.1016/j.jpeds.2026.115269
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。